United States · Platforms & data · MarketBeat

X4 Pharmaceuticals Targets 2028 Phase III Data for Mavorixafor in Chronic Neutropenia

Published by MarketBeat · United States 1 h ago

X4 Pharmaceuticals (NASDAQ:XFOR) said it expects to complete enrollment in its pivotal Phase III 4WARD trial of mavorixafor for primary chronic neutropenia, or PCN, by the end of…

Read the full article on MarketBeat Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (www.marketbeat.com)

Also worth reading

MarketWatch

‘Fancy cars hold no appeal’: We have a 99% chance of outliving our life savings. Why not spend, spend, spend?

The Motley Fool

OMA (OMAB) Q3 2026 Earnings Call Transcript

Investing.com

Earnings call transcript: Illumina beats Q3 2026 estimates but shares fall after hours

Benzinga

Toncoin (TON) Price Prediction 2025, 2026, 2027-2030

TheStreet

Stock Market Today (Oct. 29, 2026): S&P 500 falls after Alphabet and Microsoft issue divergent earnings

Stocktwits